Janssen’s Darzalex approved in EU for newly-diagnosed multiple myelomaJanssen’s Darzalex (daratumumab) has been approved in Europe as a combination therapy in newly-diagnosed patients with multiple myeloma. Share XJanssen’s Darzalex approved in EU for newly-diagnosed multiple myelomahttps://pharmaphorum.com/news/janssens-darzalex-approved-in-eu-for-multiple-myeloma/
Life with multiple myelomaMultiple myeloma patient Bob Munro (pictured below) explains what it’s like to live with the rare blood cancer and Share XLife with multiple myelomahttps://pharmaphorum.com/partner-content/life-with-multiple-myeloma/
GSK files multiple myeloma drug with FDA after phase 2 successGSK has filed for FDA approval of its potential first-in-class multiple myeloma drug belantamab mafodotin for relapsed/refractory multiple Share XGSK files multiple myeloma drug with FDA after phase 2 successhttps://pharmaphorum.com/news/gsk-files-multiple-myeloma-drug-with-fda-after-phase-2-success/
J&J gets okay for a third first-line Darzalex combo in USJohnson & Johnson continues to extend the use of its Darzalex therapy in newly-diagnosed multiple myeloma patients, getting Share XJ&J gets okay for a third first-line Darzalex combo in UShttps://pharmaphorum.com/news/jj-gets-okay-for-a-third-first-line-darzalex-combo-in-us/
GSK scores major trial win with potential multiple myeloma blockbusterGlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal Share XGSK scores major trial win with potential multiple myeloma blockbusterhttps://pharmaphorum.com/news/gsk-scores-major-trial-win-with-potential-multiple-myeloma-blockbuster/
GSK hires former Genentech expert for AI unitGlaxoSmithKline has hired computational drug design specialist Dr Kim Branson to expand its artificial intelligence and machine learning Share XGSK hires former Genentech expert for AI unithttps://pharmaphorum.com/news/gsk-hires-former-genentech-expert-for-ai-unit/
FDA reviews Sanofi’s multiple myeloma drug isatuximabThe FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for Share XFDA reviews Sanofi’s multiple myeloma drug isatuximabhttps://pharmaphorum.com/news/fda-reviews-sanofis-multiple-myeloma-drug-isatuximab/
FDA clears Karyopharm’s myeloma drug despite advisory panel rejectionThe FDA has taken the unusual step of over-ruling its own advisory committee and approving Karyopharm’s Xpovio as Share XFDA clears Karyopharm’s myeloma drug despite advisory panel rejectionhttps://pharmaphorum.com/news/fda-clears-karyopharms-myeloma-drug-despite-advisory-panel-rejection/
Janssen to develop Darzalex successor with GenmabJanssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it Share XJanssen to develop Darzalex successor with Genmabhttps://pharmaphorum.com/news/janssen-to-develop-darzalex-successor-with-genmab/
